Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

FDA Ready To Hire New Deputy Commissioner For Medical Products And Tobacco

This article was originally published in The Pink Sheet Daily

Executive Summary

The winning candidate would be the third to hold the position in two years; job notice will be corrected, though – top secret clearance is not required.

You may also be interested in...



Finally … Rachel Sherman Takes Califf's Old FDA Job

After months of speculation, FDA veteran Rachel Sherman becomes deputy commissioner for medical products and tobacco.

Califf Has Several Industry Ties To Sever Before Joining FDA

Duke cardiologist has an equity stake in two companies and consulting arrangements with at least seven others.

Califf Has Several Industry Ties To Sever Before Joining FDA

Duke cardiologist has an equity stake in two companies and consulting arrangements with at least seven others.

Related Content

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

PS076111

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel